Attention-deficit/hyperactivity disorder (ADHD) is characterized

Size: px
Start display at page:

Download "Attention-deficit/hyperactivity disorder (ADHD) is characterized"

Transcription

1 THE JOURNAL OF THE AMERICAN OSTEOPATHIC ASSOCIATION Treatment of Adults With Attention-Deficit/Hyperactivity Disorder David A. Baron, DO, MSEd Michele T. Pato, MD Rebecca L. Cyr, BA Attention-deficit/hyperactivity disorder (ADHD) is a clinically important neuropsychiatric developmental disorder that affects children, adolescents, and adults. The disorder is characterized by core symptoms of inattention, hyperactivity, distractibility, impulsivity, and impaired executive functioning. It is estimated that 2% to 5% of the adult population in the United States has ADHD. Adults with ADHD are at an increased risk for experiencing comorbid psychiatric disorders, including mood disorders, anxiety disorders, and substance use disorders. The authors provide a brief clinical overview of ADHD and the treatment of adults with this disorder. J Am Osteopath Assoc. 2011;111(11): From the Department of Psychiatry and Behavioral Sciences at Keck School of Medicine of the University of Southern California in Los Angeles. Financial Disclosures: None reported. Address correspondence to Rebecca L. Cyr, BA, Special Projects Manager, Department of Psychiatry and Behavioral Sciences, Keck School of Medicine of the University of Southern California, 2250 Alcazar St, CSC 2200, Los Angeles, CA rcyr@usc.edu Submitted March 22, 2011; final revision received June 30, 2011; accepted July 15, JAOA Vol 111 No 11 November 2011 Attention-deficit/hyperactivity disorder (ADHD) is characterized by core symptoms of inattention, hyperactivity, distractibility, and impulsivity. 1 Unlike most other psychopathologic conditions, which were originally thought to occur only in adults, ADHD was initially believed to affect only children and adolescents. Sir George Frederic Still, MD, the proclaimed father of British pediatrics, provided the first clinical description of ADHD in a series of 3 lectures given to the Royal College of Physicians in London in From then until the mid-1970s, when Wood et al 3 first described ADHD in adults, ADHD was thought to be psychic acne that an individual grew out of over time. In reality, more than 50% of children with ADHD will carry the disorder into adulthood. The initial lack of recognition that an adult form of ADHD exists can be attributed to the fact that many of the presenting symptoms seen in children morph over time (Figure 1). 4,5 An adult with ADHD is not likely to run around erratically in his or her place of work or in social settings. Instead, that person may feel restless and have a difficult time sitting still and maintaining focus. Children typically have parents and teachers to help organize their lives, but adults typically do not. Thus, common dysfunctions of adults with ADHD include their inability to organize their lives, meet deadlines, avoid impulsive behavior, and attend to boring tasks. 6 The life consequences resulting from these deficits can be devastating for patients and their families. Although the behaviors observed in children with ADHD may appear to change as they grow into adults, the core symptoms of inattention, impulsivity, and distractibility are relatively constant over time unlike symptoms of mood and anxiety disorders, which are episodic and can wax and wane. The continuous nature of ADHD symptoms helps to explain why most adults with the disorder never receive a diagnosis or treatment. It s just who I am and always have been, is a common explanation of patients with lifelong core symptoms. It is often a comorbid mood or anxiety disorder that causes an individual with ADHD to seek treatment. Attention-deficit/hyperactivity disorder responds to pharmacotherapy and behavioral therapy, particularly cognitive

2 KEY POINTS ATTENTION-DEFICIT/HYPERACTIVITY DISORDER (ADHD) affects people of all ages and IQ levels. DEFICITS OF EXECUTIVE FUNCTIONING CAN MAKE IT difficult for people to function at full capacity in academic, occupational, and social environments and in other activities of daily living. COMORBIDITY IS COMMON IN ADULTS WITH ADHD. CONSIDER A DIAGNOSIS OF ADHD IN PATIENTS presenting with any of the core symptoms (ie, distractibility, hyperactivity, impulsivity, inattention), substance abuse, and mood/anxiety disorders, as well as in patients with a long history of psychosocial dysfunction. CLOSELY MONITOR PHARMACOLOGIC TREATMENTS. LONG-ACTING/EXTENDED-RELEASE STIMULANTS OR nonstimulants are effective first-line treatments; shortacting stimulants should be avoided for adults with ADHD. NONPHARMACOLOGIC TREATMENTS, INCLUDING cognitive behavioral therapy and time-management training, should be considered for all adults with ADHD. behavioral therapy. According to a 2009 meta-analysis, 7 recent clinical reports have suggested that neurofeedback, an advanced form of biofeedback, may be effective in treating adults and children with ADHD. To our knowledge, randomized controlled clinical trials have not been highlighted in top tier peer-reviewed journals to date. Some patients report receiving benefits from life coaches who are specifically trained to assist adults with ADHD. 8 Regardless of the treatment modality selected, it is well established that untreated adults with ADHD score below average on measures of overall mental health, compared with matched adults without ADHD. In addition to the core symptoms of inattention, distractibility, impulsivity, and hyperactivity, an important area of clinical assessment when evaluating adults with ADHD should be executive functioning. 9 Executive Functioning According to the age-of-onset criteria in the Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition, Text Revision (DSM-IV-TR), individuals diagnosed as having ADHD must present with clinically impairing symptoms by age 7 years (Figure 2). 10 In actual clinical settings, however, many patients with ADHD first present for treatment in adulthood. 11,12 Faraone et al 11 question the DSM-IV age-of-onset criteria, arguing that the age is set too low. They assert that the diagnostic criteria should be revised to include patients whose condition was first diagnosed in adolescence. The key diagnostic feature is evidence of core ADHD symptoms before adulthood, even if the diagnosis was never made in childhood or early adolescence. It is now estimated that at least 4% of the adult population in the United States may have symptoms of ADHD. 13 Compared to matched individuals without ADHD, untreated patients with ADHD face serious disabilities and morbidities, including lower education levels, poorer employment records, and more partner separation and divorce. 13,14 Many of these adverse life outcomes are directly related to difficulties with executive functioning. According to Brown et al, 15 adults with ADHD experience difficulties with executive functioning on a daily basis, particularly in the areas of organizing one s routine tasks, working within deadlines, making consistent efforts, remembering, and maintaining adequate focus. To measure core executive functioning deficits in adults with ADHD, Brown 16 developed a rating scale, known as the Brown Attention Deficit Disorder (ADD) Scale for Adults. He described these deficits as being related to the following 5 core areas of executive functioning: activation, focus, effort, emotion, and memory. Barkley et al 9 expanded this concept, noting that expression of symptoms in these 5 areas can include distractibility, impulsiveness, poor concentration, lack of persistence, problems with working memory, and poor organizational skills. Biederman et al 14 performed an extensive evaluation of executive functioning in adults, focusing on measurements that were sensitive to detecting problems with sustained attention/vigilance, planning and organization, response inhibition, set shifting and categorization, selective attention and visual scanning, verbal and visual learning, and memory. The researchers tests were used to compare these areas of executive functioning among the following 4 groups of adults: adults with ADHD who did not have executive functioning problems adults with both ADHD and executive functioning problems Children Motoric hyperactivity Aggressiveness Low frustration tolerance Impulsiveness Adults Easily distracted Inattentiveness Shifts activities Easily bored Impatience Restlessness Figure 1. Developmental trends in symptoms of attention-deficit/hyperactivity disorder from childhood to adulthood. Adapted from Wilens et al 4 and Millstein et al. 5 JAOA Vol 111 No 11 November

3 Persistent pattern of inattention and/or hyperactivityimpulsivity Symptoms must be present for past 6 months Must have 6 or more symptoms of inattention and/or hyperactivity-impulsivity Some hyperactive-impulsive or inattentive symptoms that caused impairment were present before age 7 years Some impairment from symptoms must be present in 2 or more settings (eg, at home and at school or work) Clinically significant social, academic, or occupational impairment Symptoms not exclusively caused or better accounted for by another mental disorder Figure 2. Diagnostic criteria for attention-deficit/hyperactivity disorder. Adapted from the American Psychiatric Association s Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition, Text Revision (DSM-IV-TR). 10 adults without ADHD but with executive functioning problems adults with neither ADHD nor executive functioning problems Adults with both ADHD and executive functioning problems performed the worst in all measurements, and adults with neither ADHD nor executive functioning problems performed the best. In an analysis of the number of traffic tickets, traffic accidents, and arrest records of the study participants, the 2 groups with ADHD despite differences in executive Until the mid-1970s, ADHD was thought to be psychic acne that an individual grew out of over time. functioning were found to have received more traffic tickets, been involved in more traffic accidents, and been arrested more often than those without ADHD. 14 Interestingly, subtle deficits in executive functioning can affect adults with ADHD independently of intellectual capacity. Brown et al 15 studied the relationship between individuals IQ and executive functioning. The study sample included individuals who had ADHD and an IQ higher than 120, representing a group that was 1.5 standard deviations above the general population s mean IQ of 100. Eight measures of executive functioning were assessed, and the ADD Scale for Adults was administered. The study population consisted of 157 adults between ages 18 and 55 years. Analysis of the data revealed that more than 70% of the patients reported statistically significant impairment in 4 of the 5 core areas of executive functioning (activation, focus, effort, and memory). Overall, 73% of the patients reported statistically significant impairment in at least 5 of 8 additional executive functioning measures. Of note, patients with ADHD who had higher IQ scores were more functionally impaired than patients without ADHD who had lower IQ scores. 15 These reported observations on executive functioning underscore the importance of establishing an accurate diagnosis and developing an effective treatment strategy. An important research finding is that having a high IQ does not preclude an individual from having ADHD. In fact, deficits in executive functioning may be more disabling in adult patients with high IQs. Adults with high IQs even if they found ways of adapting to ADHD in childhood are often frustrated by underachievement in school and work settings, knowing that their performance does not live up to their potential. 15,17 With adequate treatment, however, life goals can be achieved or exceeded. 18 General Treatment Guidelines A Google search of treatment of adult ADHD on November 4, 2011, yielded more than 3 million results. The Internet has become a primary source of health information for patients worldwide. This development is a double-edged sword. The Internet allows easy access to some credible, evidence-based information on health. However, not all Internet content is peer reviewed, making it difficult for the public to distinguish between genuine science vs personal opinions and marketing strategies. As treating physicians, we must consider it vital to educate our patients about ADHD. Effective treatment starts with an accurate diagnosis. Although a number of excellent, valid, and reliable symptom screening techniques and diagnostic psychometric tools are available to assist physicians, an accurate diagnosis is dependent on a comprehensive interview with the patient conducted by a provider who is knowledgeable about ADHD. Extensive, and usually expensive, psychological testing is not necessary. Attaining corroborating information on patient history from family members is important to establish an accurate diagnosis. It is disappointing that, despite increased awareness among physicians that ADHD can persist into adulthood, only about 11% of adults with ADHD have received treatment. 13 After confirmation of a diagnosis of ADHD, including any comorbid psychopathologic conditions, appropriate medication therapy (Figure 3) 19 and psychotherapy should be initiated. Long-acting stimulant medications are the most widely prescribed pharmacologic treatment for patients with ADHD and are generally the first drugs of choice for adult patients. Because of the potential for abuse and the need for multiple daily dosing, short-acting stimulant medications should be 612 JAOA Vol 111 No 11 November 2011

4 Recommended Dosing Ranges Medication Proprietary Name for Adults, mg/d Long-Acting/Extended-Release Stimulants Amphetamine sulfate Adderall XR (Shire US; Wayne, PA) Dexedrine Spansule (Amedra 5-60 Pharmaceuticals; Middlesex, NJ) Vyvanse (Shire US; Wayne, PA) Methylphenidate Concerta (Janssen Pharmaceuticals; hydrochloride Titusville, NJ) Focalin XR (Novartis Pharmaceuticals; Metadate CD (UCB; Smyrna, GA) Methylin ER (Shionogi USA; Florham Park, NJ) Ritalin LA (Novartis Pharmaceuticals; Ritalin SR (Novartis Pharmaceuticals; Nonstimulants Atomoxetine hydrochloride Strattera (Eli Lilly and Co; Indianapolis, IN) Guanfacine hydrochloride Intuniv (Shire US; Wayne, PA) 1-4 used only rarely in treating adults with ADHD. For all adolescent and adult patients receiving stimulants, issues related to nonmedical use, diversion, substance abuse, and dependence should be monitored on an ongoing basis. Atomoxetine hydrochloride is a nonstimulant medication approved by the US Food and Drug Administration (FDA) for the management of ADHD in adults. 20 This drug may be particularly effective in patients with comorbid anxiety, tics, or a history of drug abuse. 21 As a nonstimulant, atomoxetine prescriptions can be renewed over the phone, allowing clinically stable patients to receive multiple refills. For patients with contraindications (eg, high abuse liability, medical conditions, known hypersensitivity), a nonstimulant should be considered. 22 When initiating pharmacotherapy, it is important for physicians to inform patients about what to expect from treatment. Clinical concerns such as decreased appetite, possible sleep problems, headache, and increased heart rate should be reviewed with patients. Patients who have a personal or family history of cardiac disease, who report passing out while exercising, or who have cardiac murmur should be screened for baseline disease, including untreated hypertension, arrhythmias, and structural cardiac defects. To our knowledge, no data exist to warrant serial electrocardiogram monitoring in otherwise heart-healthy individuals. 23 Psychotherapeutic intervention (ie, talk therapy ) is often an important component of treatment for adults with ADHD. Cognitive behavioral therapy for managing problems of focus, organization, motivation, and memory as they Figure 3. Medications used, with available proprietary brands and dosing ranges, for the treatment of adults with attentiondeficit/hyperactivity disorder. Adapted from Physicians Desk Reference (http: // relate to executive functioning has been found to be successful in adults. 11 Given the high occurrence of comorbid psychopathologic conditions in adults with ADHD, 13,22,24 a comprehensive treatment strategy is typically required. In a 2004 study, Biederman 24 found that both men and women with ADHD had much higher lifetime prevalence of major depression (27% and 36%, respectively), compared with male and female controls (4% and 6%, respectively). Similarly, Biederman 24 found that men and women with ADHD had higher lifetime prevalence of multiple (>2) anxiety disorders (46% and 52%, respectively), compared with male and female controls (10% and 15%, respectively). When comorbid conditions are present, pharmacologic treatment and psychotherapy aimed at all co-occurring disorders is important. Multiple medications may be required to achieve maximal clinical benefit. 8 Finally, all treatment strategies should be patient-centered and based on the concept of personalized medicine. For adults with ADHD, lifestyle changes should always be considered in patient care. An initial assessment of the patient for any unique lifestyle dysfunction is important. For example, an Only about 11% of adults with ADHD have received treatment. adult may be struggling in a job that requires intense concentration and attention to detail, but that same individual may enjoy success in a position that allows for less attention to detail and an emphasis on big-picture skills. Treatment should address all problematic areas, including interpersonal relationships, occupational issues, self-esteem, and social functioning. Issues related to a lifelong history of feeling like an underachiever may need to be addressed in the patient with ADHD. 18 Appropriate treatment for ADHD can positively impact a patient s marriage, job, and overall selfesteem and life functioning. JAOA Vol 111 No 11 November

5 Recommended Reading A useful book on this subject is Attention-Deficit Hyperactivity Disorder: A Handbook for Diagnosis and Treatment, by Russell A. Barkley, PhD (3rd ed, New York, NY, Guilford Press, 2005). In the book, Dr Barkley stresses differences in diagnosis and treatment between children, adolescents, and adults. Conclusion Recent epidemiologic studies report at least 4% of the adult population in the United States may have ADHD. A crucial area of clinical assessment when evaluating adults with ADHD is executive functioning. Serious life disturbances, such as relationship and occupational problems, resulting from dysfunction in executive functioning underscore the importance of establishing an accurate diagnosis and developing an effective treatment strategy for patients with ADHD. Adults with ADHD respond well to pharmacotherapy and behavioral therapy, particularly cognitive behavioral therapy (eg, managing problems of focus, organization, motivation, and memory). Short-acting stimulants should be avoided in treating adults with ADHD. Lifestyle changes should be a consideration in treatment. References 1. Hervey AS, Epstein JN, Curry JF. Neuropsychology of adults with attentiondeficit/hyperactivity disorder: a meta-analytic review. Neuropsychology. 2004;18(3): Still GF. The Goulstonian lectures on some abnormal psychical conditions in children. Lancet. 1902;159: Wood DR, Reimherr FW, Wender PH, Johnson GE. Diagnosis and treatment of minimal brain dysfunction in adults: a preliminary report. Arch Gen Psychiatry. 1976;33(12): Wilens TE, Biederman J, Spencer TJ. Attention-deficit/hyperactivity disorder in youth. In: Hendren RL, ed. Disruptive Behavior Disorders in Children and Adolescents. Arlington, VA: American Psychiatric Publishing; Millstein RB, Wilens TE, Biederman J, Spencer TJ. Presenting ADHD symptoms and subtypes in clinically referred adults with ADHD. J Attention Disord. 1997;2(3): McGough JJ, Smalley SL, McCracken JT, et al. Psychiatric comorbidity in adult attention deficit hyperactivity disorder: findings from multiplex families. Am J Psychiatry. 2005;162(9): Arns M, de Ridder S, Strehl U, Breteler M, Coenen A. Efficacy of neurofeedback treatment in ADHD: the effects on inattention, impulsivity and hyperactivity: a meta-analysis. Clin EEG Neurosci. 2009;40(3): Barkley RA. Attention-Deficit Hyperactivity Disorder: A Handbook for Diagnosis and Treatment. 3rd ed. New York, NY: Guilford Press; Barkley RA, Murphy KR, Fischer M. ADHD in Adults: What the Science Says. New York, NY: Guilford Press; American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition, Text Revision (DSM-IV-TR). Washington, DC: American Psychiatric Association; 2000: Faraone SV, Biederman J, Spencer T, et al. Diagnosing adult attention deficit hyperactivity disorder: are late onset and subthreshold diagnoses valid? Am J Psychiatry. 2006;163(10): Faraone SV, Antshel KM. Diagnosing and treating attention-deficit/hyperactivity disorder in adults. World Psychiatry. 2008;7(3): Kessler RC, Adler L, Barkley R, et al. The prevalence and correlates of adult ADHD in the United States: results from the National Comorbidity Survey Replication. Am J Psychiatry. 2006;163(4): Biederman J, Petty C, Fried R, et al. Impact of psychometrically defined deficits of executive functioning in adults with attention deficit hyperactivity disorder. Am J Psychiatry. 2006;163(10): Brown TE, Reichel PC, Quinlan DM. Executive function impairments in high IQ adults with ADHD [published online ahead of print May 6, 2009]. J Atten Disord. 2009;13(2): Brown TE. Brown Attention-Deficit Disorder Scales for Adolescents and Adults. San Antonio, TX: Psychological Corporation; Antshel KM, Faraone SV, Maglione K, et al. Executive functioning in high-iq adults with ADHD. Psychol Med. 2010;40(11): Baron DA. The gold medal face of ADHD. J Atten Disord. 2010;13(4): Physicians Desk Reference. 64th ed. Montvale, NJ: PDR Network LLC; Brown TE, Holdnack J, Saylor K, et al. Effect of atomoxetine on executive function impairments in adults with ADHD [published online ahead of print December 21, 2009]. J Atten Disord. 2011;15(2): Wilens TE, Faraone SV, Biederman J, Gunawardene S. Does stimulant therapy of attention-deficit/hyperactivity disorder beget later substance abuse? a meta-analytic review of the literature. Pediatrics. 2003;111(1): Baron DA, Bizamcer AN. The relationship of ADHD, its treatment, and substance use. Behav Health Manage. 2004;24(4):S1-S Otto MA. Sudden death risk with ADHD stimulants is low: if answer to four questions is yes, don t hesitate to enlist help of a pediatric cardiologist. Clinical Psychiatry News. 2011;39(2): Biederman J. Impact of comorbidity in adults with attention-deficit/hyperactivity disorder. J Clin Psychiatry. 2004;65(suppl 3):3-7. JAOA Online Archives Archives of JAOA The Journal of the American Osteopathic Association content as far back as 1950 are available online at Beginning with the January 2000 issue, JAOA articles, letters, and other contributions are available in full text, PDF documents, or both. In addition, members of the American Osteopathic Association and JAOA subscribers can access content from the past 12 months free of charge. 614 JAOA Vol 111 No 11 November 2011

QUANTITY LIMIT CRITERIA

QUANTITY LIMIT CRITERIA DRUG CLASS (ADHD) AGENTS BRAND NAME (generic) QUANTITY LIMIT CRITERIA ATTENTION DEFICIT HYPERACTIVITY DISORDER ADDERALL (amphetamine mixture) ADDERALL XR (amphetamine extended-release mixture) ADZENYS

More information

Psychopharmacology of ADHD. Copyright 2006 Neuroscience Education Institute. All rights reserved.

Psychopharmacology of ADHD. Copyright 2006 Neuroscience Education Institute. All rights reserved. Psychopharmacology of ADHD Persistence (Predicted Value) Persistence of ADHD Into Adulthood 90 80 70 60 50 40 30 20 10 0 NA 10 15 20 25 30 Age at Follow-Up Syndromatic Persistence Symptomatic Persistence

More information

What are the most common signs of ADHD? And what are the most common medication interventions?

What are the most common signs of ADHD? And what are the most common medication interventions? What are the most common signs of ADHD? And what are the most common medication interventions? Bennett Gertz, MD, FAAP Developmental Behavioral Pediatrician Children s Developmental Health Services Albertina

More information

The Use of ADHD Medication in the Pediatric Population

The Use of ADHD Medication in the Pediatric Population The Use of ADHD Medication in the Pediatric Population Shirin Madzhidova, PharmD Pediatric Pharmacotherapy Fellow Nova Southeastern University Objectives Discuss the importance of treatment with medications

More information

Attention Deficit Hyperactivity Disorder (ADHD) BY MARK FABER M.D.

Attention Deficit Hyperactivity Disorder (ADHD) BY MARK FABER M.D. Attention Deficit Hyperactivity Disorder (ADHD) BY MARK FABER M.D. PREVALENCE & STATISTICS 6-8% of all children have ADHD (CDC Statistical Data) Age of onset: 7 years old (Prior DSM-IV) 12 years old (Current

More information

Facts about ADHD drugs as treatment

Facts about ADHD drugs as treatment Facts about ADHD drugs as treatment Common ADHD drugs as treatment Medication Stimulants Methylphenidate Dexmethylphenidate Amphetamine Non-Stimulants Straterra Guanfacine ER (Intuniv) Clonidine (Kapvay)

More information

About AD/HD. American Osteopathic College of Occupational and Preventive Medicine 2015 Mid Year Educational Conference, Ft Lauderdale, Florida J-1

About AD/HD. American Osteopathic College of Occupational and Preventive Medicine 2015 Mid Year Educational Conference, Ft Lauderdale, Florida J-1 Adolescent and Adult ADHD: An Update on Impact, Diagnosis and Treatment Joel L. Young, M.D. Medical Director: Rochester Center for Behavioral Medicine Teaching Faculty: Wayne State University School of

More information

UnitedHealthcare Pharmacy Clinical Pharmacy Programs. Program Number 2017 P Prior Authorization/Notification CNS Stimulants

UnitedHealthcare Pharmacy Clinical Pharmacy Programs. Program Number 2017 P Prior Authorization/Notification CNS Stimulants UnitedHealthcare Pharmacy Clinical Pharmacy Programs Program Number 2017 P 1020-6 Program Prior Authorization/Notification CNS Stimulants Medication Adderall* (amphetamine-dextroamphetamine mixed salts),

More information

MANAGEMENT OF ADHD IN ADULTS

MANAGEMENT OF ADHD IN ADULTS MANAGEMENT OF ADHD IN ADULTS RICHARD MOLDAWSKY, M.D. I Can t Focus on Anything Except Getting My Adderall 1 ASSUMPTIONS FOR TODAY Most of us don t work 2 W s without seeing a person with ADHD You are familiar

More information

Driving to Distraction

Driving to Distraction Driving to Distraction New Research on the Impact of ADHD and ADHD Medications on Driving performance Daniel J. Cox, Ph.D., A.B.P.P Professor, Departments of Psychiatric and Internal Medicine Director,

More information

AD/HD is a mental disorder, and it often lasts from

AD/HD is a mental disorder, and it often lasts from short version10 WHAT WE KNOW Managing Medication for Adults with AD/HD AD/HD is a mental disorder, and it often lasts from childhood into adulthood. Medication is the basic part of treatment for adults.

More information

Ask The Shrink: ADHD

Ask The Shrink: ADHD Ask The Shrink: ADHD Theodore A. Petti, MD Professor of Psychiatry Division of Child and Adolescent Psychiatry Robert Wood Johnson Medical School PPC Hub Psychiatrist Hackensack Meridian Hubs @ Saint Peter'

More information

For more than 100 years, extremely hyperactive

For more than 100 years, extremely hyperactive 8 W H A T W E K N O W AD/HD Predominantly Inattentive Type For more than 100 years, extremely hyperactive children have been recognized as having behavioral problems. In the 1970s, doctors recognized that

More information

Individuals wishing to seek an evaluation for ADHD

Individuals wishing to seek an evaluation for ADHD 9 WHAT WE KNOW Diagnosis of ADHD in Adults Individuals wishing to seek an evaluation for ADHD should use this information and resource sheet as a set of guidelines for what to expect from the clinician

More information

Update on the Treatment of ADHD 2019

Update on the Treatment of ADHD 2019 Update on the Treatment of ADHD 2019 James H. Beard, Jr., M.D, FAAP Developmental-Behavioral Pediatrician Division of Developmental Pediatrics The Rights of ADHD The right diagnosis of ADHD and co morbidities

More information

Practical Psychopharmacology for More Complex Mental Health Presentations

Practical Psychopharmacology for More Complex Mental Health Presentations MINISTRY OF CHILDREN AND YOUTH SERVICES Practical Psychopharmacology for More Complex Mental Health Presentations Part 1: Stimulants Dr. Ajit Ninan & Joel Lamoure 1 Practical Psychopharmacology for More

More information

Comorbidity With Substance Abuse P a g e 1

Comorbidity With Substance Abuse P a g e 1 Comorbidity With Substance Abuse P a g e 1 Comorbidity With Substance Abuse Introduction This interesting session provided an overview of recent findings in the diagnosis and treatment of several psychiatric

More information

Presented by the National Resource Center on ADHD

Presented by the National Resource Center on ADHD Presented by the National Resource Center on ADHD Timothy E. Wilens, M.D. Massachusetts General Hospital Harvard Medical School Save 25% if you join/rejoin CHADD Use Promo Code: JANA14 If you are currently

More information

Perspective Truth on ADHD & Medications. Thomas L. Matthews, M.D. Associate Dean of Student Affairs Professor of Psychiatry

Perspective Truth on ADHD & Medications. Thomas L. Matthews, M.D. Associate Dean of Student Affairs Professor of Psychiatry Perspective Truth on ADHD & Medications Thomas L. Matthews, M.D. Associate Dean of Student Affairs Professor of Psychiatry Disclosures National Institute of Health ADHD and Aggression Study Co- Investigator

More information

TOOL KIT FOR THE MANAGEMENT OF ADULT ATTENTION DEFICIT/ HYPERACTIVITY DISORDER (ADHD)

TOOL KIT FOR THE MANAGEMENT OF ADULT ATTENTION DEFICIT/ HYPERACTIVITY DISORDER (ADHD) TOOL KIT FOR THE MANAGEMENT OF ADULT ATTENTION DEFICIT/ HYPERACTIVITY DISORDER (ADHD) TOOL KIT FOR THE MANAGEMENT OF ADULT ATTENTION-DEFICIT/HYPERACTIVITY DISORDER (ADHD) The clinical tool kit is intended

More information

Pharmacy Prior Authorization Clinical Guideline for Attention Deficit Disorder/Attention Deficit Hyperactivity CNS Stimulants

Pharmacy Prior Authorization Clinical Guideline for Attention Deficit Disorder/Attention Deficit Hyperactivity CNS Stimulants AETNA BETTER HEALTH Pharmacy Prior Authorization Clinical Guideline for Attention Deficit Disorder/Attention Deficit Hyperactivity CNS Stimulants Formulary amphetamine/dextroamphetamine IR, ER (generic

More information

Objectives. What is ADHD? Introduction to Adult ADHD

Objectives. What is ADHD? Introduction to Adult ADHD Introduction to Adult ADHD Virginia Newton, Ph.D., R.Psych. Brentwood Psychological Services www.brentwoodpsych.com (780) 232-2489 August 15, 2018 11 Objectives Learn the differences between childhood

More information

The shift in nosology from the Diagnostic PROCEEDINGS FROM CHILDHOOD TO ADOLESCENCE: DIAGNOSIS AND COMORBIDITY ISSUES * Thomas J. Spencer, MD ABSTRACT

The shift in nosology from the Diagnostic PROCEEDINGS FROM CHILDHOOD TO ADOLESCENCE: DIAGNOSIS AND COMORBIDITY ISSUES * Thomas J. Spencer, MD ABSTRACT FROM CHILDHOOD TO ADOLESCENCE: DIAGNOSIS AND COMORBIDITY ISSUES * Thomas J. Spencer, MD ABSTRACT Attention-deficit/hyperactivity disorder (ADHD) tends to manifest differently in adolescents than in children,

More information

2013 Virtual AD/HD Conference 1

2013 Virtual AD/HD Conference 1 Medication for ADHD & Coexisting Conditions Dr. Kenny Handelman Child, Adolescent & Adult Psychiatrist Halton Healthcare Adjunct Professor of Psychiatry, University of Western Ontario www.drkenny.com www.adhdpodcast.com

More information

Citation for published version (APA): Jónsdóttir, S. (2006). ADHD and its relationship to comorbidity and gender. s.n.

Citation for published version (APA): Jónsdóttir, S. (2006). ADHD and its relationship to comorbidity and gender. s.n. University of Groningen ADHD and its relationship to comorbidity and gender Jónsdóttir, Sólveig IMPORTANT NOTE: You are advised to consult the publisher's version (publisher's PDF) if you wish to cite

More information

GA KS KY LA MD NJ NV NY TN TX WA Applicable X N/A N/A X N/A X X X X X X N/A N/A X *FHK- Florida Healthy Kids. ADHD Narcolepsy

GA KS KY LA MD NJ NV NY TN TX WA Applicable X N/A N/A X N/A X X X X X X N/A N/A X *FHK- Florida Healthy Kids. ADHD Narcolepsy Override(s) Prior Authorization ADHD Narcolepsy Approval Duration 1 year *Louisiana, Washington and Maryland Medicaid See State Specific Information Below Medications Atomoxetine: Strattera generic Clonidine

More information

Humberto Nagera M.D. Director, The Carter-Jenkins Center Psychoanalyst, Children, Adolescents and Adults Professor of Psychiatry at USF Professor

Humberto Nagera M.D. Director, The Carter-Jenkins Center Psychoanalyst, Children, Adolescents and Adults Professor of Psychiatry at USF Professor The Carter Jenkins Center presents 1 Humberto Nagera M.D. Director, The Carter-Jenkins Center Psychoanalyst, Children, Adolescents and Adults Professor of Psychiatry at USF Professor Emeritus of Psychiatry

More information

Attention Deficit Hyperactivity Disorder Overview and New Perspectives

Attention Deficit Hyperactivity Disorder Overview and New Perspectives 1st Annual Regional Psychiatry Conference Psychiatry for the Non-Psychiatrist Attention Deficit Hyperactivity Disorder Overview and New Perspectives Thomas B. Henry, MD Board Certified Child & Adolescent

More information

Pharmacologic Management of ADHD

Pharmacologic Management of ADHD Pharmacologic Management of ADHD CHADD Presentation April 13, 2015 Peter J Chung, MD, FAAP Developmental-Behavioral Pediatrician* Assistant Clinical Professor of Pediatrics University of California Irvine

More information

ADHD Stimulant Step Therapy Program

ADHD Stimulant Step Therapy Program ADHD Stimulant Step Therapy Program Policy Number: 5.01.592 Last Review: 7/2018 Origination: 7/2017 Next Review: 7/2019 Policy Blue Cross and Blue Shield of Kansas City (Blue KC) will provide coverage

More information

Is ADHD Always a Childhood Onset Disorder? Towards Understanding Adult Onset ADHD

Is ADHD Always a Childhood Onset Disorder? Towards Understanding Adult Onset ADHD Is ADHD Always a Childhood Onset Disorder? Towards Understanding Adult Onset ADHD Joseph Biederman, MD Professor of Psychiatry Harvard Medical School Chief, Clinical and Research Programs in Pediatric

More information

Individuals with attention-deficit/hyperactivity

Individuals with attention-deficit/hyperactivity National Resource Center on AD HD A program of CHADD 3 WHAT WE KNOW Managing Medication for Children and Adolescents with AD/HD * Individuals with attention-deficit/hyperactivity disorder (AD/HD) experience

More information

Drug Class Review. Pharmacologic Treatments for Attention Deficit Hyperactivity Disorder

Drug Class Review. Pharmacologic Treatments for Attention Deficit Hyperactivity Disorder Drug Class Review Pharmacologic Treatments for Attention Deficit Hyperactivity Disorder Final Update 5 Report July 2015 The purpose of reports is to make available information regarding the comparative

More information

Individuals with attention-deficit/hyperactivity

Individuals with attention-deficit/hyperactivity National Resource Center on AD HD A program of CHADD 3 WHAT WE KNOW Managing Medication for Children and Adolescents with AD/HD * Individuals with attention-deficit/hyperactivity disorder (AD/HD) experience

More information

EFFECTS OF ADHD ON EARLY LEARNING AND ACDEMIC PERFORMANCE 1

EFFECTS OF ADHD ON EARLY LEARNING AND ACDEMIC PERFORMANCE 1 EFFECTS OF ADHD ON EARLY LEARNING AND ACDEMIC PERFORMANCE 1 The Effects of ADHD on Learning and Academic Performance in the Pre- and Elementary School Years. Christopher Kalogeropoulos November 19, 2012

More information

Pharmacotherapy of ADHD Across the Lifecycle: Stimulants

Pharmacotherapy of ADHD Across the Lifecycle: Stimulants Pharmacotherapy of ADHD Across the Lifecycle: Stimulants Thomas J. Spencer, MD Massachusetts General Hospital Harvard Medical School Percent Change (Bmax/Kd) DVR Images Obtained with [ 11 C]Raclopride

More information

35 mg NF -- Dextroamphetamine Sulfate IR Tablets: Zenzedi IR Ttablets: Dextroamphetamine Sulfate ER Capsules: 15 mg ProCentra Solution.

35 mg NF -- Dextroamphetamine Sulfate IR Tablets: Zenzedi IR Ttablets: Dextroamphetamine Sulfate ER Capsules: 15 mg ProCentra Solution. MEDICATION COVERAGE POLICY PHARMACY AND THERAPEUTICS ADVISORY COMMITTEE POLICY: ADHD Medications P&T DATE 12/13/2017 CLASS: Psychiatric Disorders REVIEW HISTORY 12/16, 9/15, 5/12, 5/10, LOB: MCL (MONTH/YEAR)

More information

Pharmacy Medical Necessity Guidelines: CNS Stimulant Medications

Pharmacy Medical Necessity Guidelines: CNS Stimulant Medications Pharmacy Medical Necessity Guidelines: CNS Stimulant Medications Effective: June 1, 2017 Prior Authorization Required Type of Review Care Management Not Covered Type of Review Clinical Review Pharmacy

More information

TRANSMITTED BY FACSIMILE

TRANSMITTED BY FACSIMILE DEPARTMENT OF HEALTH & HUMAN SERVICES Public Health Service Food and Drug Administration Rockville, MD 20857 TRANSMITTED BY FACSIMILE Sue Duvall, RN, MPA Associate Director, Drug Regulatory Affairs Pharmaceuticals

More information

Central Nervous System Stimulants Drug Class Prior Authorization Protocol

Central Nervous System Stimulants Drug Class Prior Authorization Protocol Line of Business: Medi-Cal Effective Date: August 16, 2017 Revision Date: August 16, 2017 Central Nervous System Stimulants Drug Class Prior Authorization Protocol This policy has been developed through

More information

Could I Have Attention-Deficit/ Hyperactivity Disorder (ADHD)?

Could I Have Attention-Deficit/ Hyperactivity Disorder (ADHD)? Could I Have Attention-Deficit/ Hyperactivity Disorder (ADHD)? Finding an Answer to ADHD as an Adult Do you feel that you have struggled throughout your life with poor concentration, inattention, impulsivity,

More information

Dr S H Jawed Consultant General Adult Psychiatrist, Dorothy Pattison Hospital, Walsall Joint Lead Consultant for

Dr S H Jawed Consultant General Adult Psychiatrist, Dorothy Pattison Hospital, Walsall Joint Lead Consultant for Dr S H Jawed Syed.Jawed@dwmh.nhs.uk 01922607039 Consultant General Adult Psychiatrist, Dorothy Pattison Hospital, Walsall Joint Lead Consultant for Adult Neurodevelopmental Service, DWMHP NHS Trust Regional

More information

Current Research on the Effective Treatment of. Attention-Deficit/Hyperactivity Disorder. Carolyn Micheli

Current Research on the Effective Treatment of. Attention-Deficit/Hyperactivity Disorder. Carolyn Micheli ADHD Treatment 1 RUNNING HEAD: ADHD Treatment Current Research on the Effective Treatment of Attention-Deficit/Hyperactivity Disorder Carolyn Micheli ADHD Treatment 2 Abstract This paper will explore Attention-Deficit/Hyperactivity

More information

Does prescribing stimulants to patients with attention-deficit/hyperactivity

Does prescribing stimulants to patients with attention-deficit/hyperactivity Do stimulants for ADHD increase the risk of substance use disorders? For some patients, stimulants might protect against future SUDs Shailesh Jain, MD, MPH, ABDA Regional Chair Associate Professor Department

More information

Pharmacy Medical Necessity Guidelines: ADHD CNS Stimulant Medications

Pharmacy Medical Necessity Guidelines: ADHD CNS Stimulant Medications Pharmacy Medical Necessity Guidelines: ADHD CNS Stimulant Medications Effective: January 1, 2018 Prior Authorization Required Type of Review Care Management Not Covered Type of Review Clinical Review Pharmacy

More information

Attention Deficit Hyperactivity Disorder (ADHD) in Children under Age 6

Attention Deficit Hyperactivity Disorder (ADHD) in Children under Age 6 in Children under Age 6 Level 0 Conduct comprehensive assessment and provide psychoeducation about ADHD, including clearly defined treatment expectations. Consider co-morbid developmental language disorder,

More information

AD/HD Across the Lifespan. Michael F. Finkel MD, FAAN. Department of Neurology. Medical and Surgical Specialists Naples, Florida.

AD/HD Across the Lifespan. Michael F. Finkel MD, FAAN. Department of Neurology. Medical and Surgical Specialists Naples, Florida. AD/HD Across the Lifespan Michael F. Finkel MD, FAAN. Department of Neurology. Medical and Surgical Specialists Naples, Florida. Worldwide Prevalence of ADHD Is 3% to 7% Studies of ADHD prevalence United

More information

ADHD Part II: Managing Comorbities

ADHD Part II: Managing Comorbities ADHD Part II: Managing Comorbities Brett Johnson, MD Staff Psychiatrist Rady Children s Behavioral Crisis Center Assistant Clinical Professor (Voluntary), UCSD January 26, 2011 Financial Disclosure I have

More information

Individuals with attention-deficit/hyperactivity

Individuals with attention-deficit/hyperactivity 3 W H A T W E K N O W Managing Medication for Children and Adolescents with AD/HD * Individuals with attention-deficit/hyperactivity disorder (AD/HD) experience chronic problems with inattention and/or

More information

Effectively Recognizing and Managing ADHD in Adolescents. Educational Objectives

Effectively Recognizing and Managing ADHD in Adolescents. Educational Objectives Educational Objectives After completing this activity, the participant should be better able to: Explain how the proper recognition and management of ADHD in adolescents by MCOs can improve clinical outcomes

More information

ADHD and Substance Use Disorders: An Intoxicating Combination

ADHD and Substance Use Disorders: An Intoxicating Combination ADHD and Substance Use Disorders: An Intoxicating Combination Timothy E. Wilens, MD Chief, Division of Child & Adolescent Psychiatry Director, Center for Addiction Medicine Massachusetts General Hospital

More information

Drug Class Review Pharmacologic Treatments for Attention Deficit Hyperactivity Disorder

Drug Class Review Pharmacologic Treatments for Attention Deficit Hyperactivity Disorder Drug Class Review Pharmacologic Treatments for Attention Deficit Hyperactivity Disorder Final Report Update 3 September 2009 Update 2: November 2007 Update 1: May 2006 Original Report: September 2005 The

More information

About ADHD. National Resource Center on ADHD A Program of CHADD

About ADHD. National Resource Center on ADHD A Program of CHADD About ADHD Everybody can have difficulty sitting still, paying attention or controlling impulsive behavior once in a while. For some people, however, the problems are so pervasive and persistent that they

More information

Trouble shooting medication adjustment and side effect management in children with ADHD

Trouble shooting medication adjustment and side effect management in children with ADHD Trouble shooting medication adjustment and side effect management in children with ADHD Drs. Joanna Holland and Sarah Manos 44 th Annual Dalhousie Spring Refresher April 5, 2018 Disclosure We have no disclosures

More information

ORIGINAL INVESTIGATION. Attention-Deficit/Hyperactivity Disorder in Adults. A Survey of Current Practice in Psychiatry and Primary Care

ORIGINAL INVESTIGATION. Attention-Deficit/Hyperactivity Disorder in Adults. A Survey of Current Practice in Psychiatry and Primary Care ORIGINAL INVESTIGATION Attention-Deficit/Hyperactivity Disorder in Adults A Survey of Current Practice in Psychiatry and Primary Care Stephen V. Faraone, PhD; Thomas J. Spencer, MD; C. Brendan Montano,

More information

ADHD Training for General Practitioners

ADHD Training for General Practitioners ADHD Training for General Practitioners Learning Objectives Understand the stigma surrounding ADHD and develop ability to challenge stigma. Understand your role in the ADHD pathway. Understand what you

More information

Is ADHD Always a Childhood Onset Disorder? Towards Understanding Adult Onset ADHD

Is ADHD Always a Childhood Onset Disorder? Towards Understanding Adult Onset ADHD Is ADHD Always a Childhood Onset Disorder? Towards Understanding Adult Onset ADHD Joseph Biederman, MD Professor of Psychiatry Harvard Medical School Chief, Clinical and Research Programs in Pediatric

More information

Week 2: Disorders of Childhood

Week 2: Disorders of Childhood Week 2: Disorders of Childhood What are neurodevelopmental disorders? A group of conditions with onset in the developmental period Disorders of the brain The disorders manifest early in development, often

More information

Presented by the. National Resource Center on ADHD

Presented by the. National Resource Center on ADHD Presented by the National Resource Center on ADHD www.help4adhd.org (800) 233-4050 Daniel Cox, PhD Director of the Virginia Driving Safety Laboratory Professor of Psychiatric & Internal Medicine, University

More information

Title: ADHD: Symptom Reduction in Follow up Period CMS ID: PP3 NQF #: N/A

Title: ADHD: Symptom Reduction in Follow up Period CMS ID: PP3 NQF #: N/A Source(s) Office of the National Coordinator for Health Information Technology/Centers for Medicare & Medicaid Services Measure Domain Effective Clinical Care: Outcome Brief Abstract Description Percentage

More information

studied and the number of sources used to establish a diagnosis (home, school, clinics, etc.). The absence of laboratory tests or neuroimaging

studied and the number of sources used to establish a diagnosis (home, school, clinics, etc.). The absence of laboratory tests or neuroimaging LEND Brief Attention deficit hyperactivity disorder Fall 2013 1 LEND Brief Attention Deficit Hyperactivity Disorder Fall 2013 INTRODUCTION By Michael I. Reiff, MD, FAPP & Martin T. Stein, MD, FAPP Overactive

More information

Adult Attention-Deficit/ Hyperactivity Disorder: Practical Treatment Guidelines

Adult Attention-Deficit/ Hyperactivity Disorder: Practical Treatment Guidelines Adult Attention-Deficit/ Hyperactivity Disorder: Practical Treatment Guidelines Umesh Jain B.Sc., M.D., F.R.C.P.(C), D.A.B.P.N., Ph.D., M.Ed. (Cand.) Hospital for Sick Children /Centre for Addiction and

More information

DEAF CHILDREN WITH ADHD AND LEARNING DIFFICULTIES

DEAF CHILDREN WITH ADHD AND LEARNING DIFFICULTIES DEAF CHILDREN WITH ADHD AND LEARNING DIFFICULTIES Scott R. Smith, MD, MPH Developmental-Behavioral Pediatrician University of Rochester Medical Center Common Complaints about Children with Problems Your

More information

Attention-Deficit/Hyperactivity Disorder in Children and Adults Advances in Psychotherapy

Attention-Deficit/Hyperactivity Disorder in Children and Adults Advances in Psychotherapy Attention-Deficit/Hyperactivity Disorder in Children and Adults Advances in Psychotherapy Questions from chapter 1 1) For a diagnosis of ADHD, some symptoms that cause impairment must be present before

More information

Understanding the Challenges of Managing Mental Health in the Workplace With a Focus on ADHD

Understanding the Challenges of Managing Mental Health in the Workplace With a Focus on ADHD Understanding the Challenges of Managing Mental Health in the Workplace With a Focus on ADHD Dr. Don Duncan Clinical Director BC Interior ADHD Clinic Kelowna, BC Mental Health Summit Vancouver, BC December

More information

Parents Guide to ADHD Medications. Copyright Child Mind Institute

Parents Guide to ADHD Medications. Copyright Child Mind Institute Copyright 2017. Child Mind Institute Children with attention-deficit hyperactivity disorder (ADHD) find it unusually difficult to concentrate on tasks, to pay attention, to sit still and to control impulsive

More information

F O C A L I N P R O D U C T M O N O G R A P H C H NO HCl

F O C A L I N P R O D U C T M O N O G R A P H C H NO HCl FOCALIN PRODUCT MONOGRAPH C 14 H 19 NO 2 HCl FOCALIN PRODUCT MONOGRAPH C 14 H 19 NO 2 HCl CONTENTS Introduction..........................................................................1 Background of

More information

Page: 1 of 5. Methylphenidate also has an off-label indication for depression, although published trials are limited in size and duration (12).

Page: 1 of 5. Methylphenidate also has an off-label indication for depression, although published trials are limited in size and duration (12). Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.06.25 Page: 1 of 5 Last Review Date: June 19, 2015 Description Concerta / Daytrana / Metadate CD / Metadate

More information

Methylphenidate Dexmethylphenidate

Methylphenidate Dexmethylphenidate Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.60.25 Yeah Subject: Methylphenidates Page: 1 of 6 Last Review Date: September 15, 2017 Methylphenidate

More information

OVERVIEW FOOD AND DRUG ADMINISTRATION-APPROVED INDICATIONS

OVERVIEW FOOD AND DRUG ADMINISTRATION-APPROVED INDICATIONS Pharmacy Medical Necessity Guidelines: Effective: September 18, 2017 Prior Authorization Required Type of Review Care Management Not Type of Review Clinical Review Pharmacy (RX) or Medical (MED) Benefit

More information

Consolidated Comprehensive Research Plan: Pharmacologic Treatment of Attention Deficit Hyperactivity Disorder in Adults

Consolidated Comprehensive Research Plan: Pharmacologic Treatment of Attention Deficit Hyperactivity Disorder in Adults FINAL Consolidated Comprehensive Research Plan: Pharmacologic Treatment of Attention Deficit Hyperactivity Disorder in Adults April 29 th, 2015 30 Bond Street, Toronto ON, M5B 1W8 www.odprn.ca info@odprn.ca

More information

Pharmacy Medical Necessity Guidelines: ADHD CNS Stimulant Medications

Pharmacy Medical Necessity Guidelines: ADHD CNS Stimulant Medications Pharmacy Medical Necessity Guidelines: ADHD CNS Stimulant Medications Effective: November 13, 2018 Prior Authorization Required Type of Review Care Management Not Covered Type of Review Clinical Review

More information

PHARMACY COVERAGE GUIDELINES ORIGINAL EFFECTIVE DATE: 3/15/18 SECTION: DRUGS LAST REVIEW DATE: 3/15/18 LAST CRITERIA REVISION DATE: ARCHIVE DATE:

PHARMACY COVERAGE GUIDELINES ORIGINAL EFFECTIVE DATE: 3/15/18 SECTION: DRUGS LAST REVIEW DATE: 3/15/18 LAST CRITERIA REVISION DATE: ARCHIVE DATE: DYANAVEL XR (amphetamine) extended-release oral suspension Coverage for services, procedures, medical devices and drugs are dependent upon benefit eligibility as outlined in the member's specific benefit

More information

The Adolescent with ADHD: Managing Transition

The Adolescent with ADHD: Managing Transition The Adolescent with ADHD: Managing Transition Professor Philip Hazell University of Sydney and Rivendell Child, Adolescent and Family Mental Health Service Disclosure Statement: Philip Hazell Source Eli

More information

ADHD: MORE THAN ATTENTION PROBLEM JULIE STECK, PH.D., HSPP CRG/CHILDREN S RESOURCE GROUP

ADHD: MORE THAN ATTENTION PROBLEM JULIE STECK, PH.D., HSPP CRG/CHILDREN S RESOURCE GROUP ADHD: MORE THAN ATTENTION PROBLEM JULIE STECK, PH.D., HSPP CRG/CHILDREN S RESOURCE GROUP WWW.CHILDRENSRESOURCEGROUP.COM UNDERSTANDING THE NATURE OF ADHD IS CRITICAL TO TREATING THE DISORDER HYPERACTIVITY

More information

PRESCRIBING PHYSICIANS PLEASE READ

PRESCRIBING PHYSICIANS PLEASE READ PRESCRIBING PHYSICIANS PLEASE READ USADA s mission is to protect the rights of clean athletes. Some athletes need to use stimulants to manage ADD/ADHD and the anti-doping community acknowledges and respects

More information

Methylphenidate also has an off-label indication for depression, although published trials are limited in size and duration (14).

Methylphenidate also has an off-label indication for depression, although published trials are limited in size and duration (14). Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.60.25 Yeah Subject: Methylphenidates Page: 1 of 5 Last Review Date: December 2, 2016 Methylphenidate

More information

Contents Definition and History of ADHD Causative Factors

Contents Definition and History of ADHD Causative Factors 1 Definition and History of ADHD................... 1 Brain Damage Syndromes........................ 1 Alternative Terms for ADHD...................... 2 Evolution of Present Concept of ADHD................

More information

PharmaPoint: Attention Deficit Hyperactivity Disorder (ADHD) - Global Drug Forecast and Market Analysis to 2024

PharmaPoint: Attention Deficit Hyperactivity Disorder (ADHD) - Global Drug Forecast and Market Analysis to 2024 PharmaPoint: Attention Deficit Hyperactivity Disorder (ADHD) - Global Drug Forecast and Market Analysis to 2024 PharmaPoint: Attention Deficit Hyperactivity Disorder (ADHD) - Global Drug Forecast and Market

More information

Executive Functions and ADHD

Executive Functions and ADHD Image by Photographer s Name (Credit in black type) or Image by Photographer s Name (Credit in white type) Executive Functions and ADHD: Theory Underlying the New Brown Executive Functions/Attention Scales

More information

PAL Conference Cle Elum March 2015

PAL Conference Cle Elum March 2015 Source Research Funding Books, Intellectual Property Advisor/ Consultant Speakers Bureau Employee In-kind Services (example: travel) Stock or Equity Honorarium or expenses for this presentation or meeting

More information

Adult ADHD for GPs. Maria Mazfari Associate Nurse Consultant Adult ADHD Tina Profitt Clinical Nurse Specialist Adult ADHD

Adult ADHD for GPs. Maria Mazfari Associate Nurse Consultant Adult ADHD Tina Profitt Clinical Nurse Specialist Adult ADHD Adult ADHD for GPs Maria Mazfari Associate Nurse Consultant Adult ADHD Tina Profitt Clinical Nurse Specialist Adult ADHD I m a Believer.. Are You? What is ADHD? ADHD is a valid clinical condition defined

More information

Methylphenidate Dexmethylphenidate

Methylphenidate Dexmethylphenidate Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 Subject: Methylphenidates Page: 1 of 7 Last Review Date: November 30, 2018 Methylphenidate Dexmethylphenidate

More information

OH, Adolescents and Attention Deficit Hyperactivity Disorder (ADHD) How do you deal with them? Presented By: Todd Twogood MD, FAAP

OH, Adolescents and Attention Deficit Hyperactivity Disorder (ADHD) How do you deal with them? Presented By: Todd Twogood MD, FAAP OH, Adolescents and Attention Deficit Hyperactivity Disorder (ADHD) How do you deal with them? Presented By: Todd Twogood MD, FAAP Teenagers Time of Transformation Allergy to Parents The Real Self Looks

More information

ADHD and Comorbid Conditions A Conceptual Model

ADHD and Comorbid Conditions A Conceptual Model ADHD and Comorbid Conditions A Conceptual Model Thomas E. Brown PhD. Assistant Clinical Professor of Psychiatry, Yale University School of Medicine and Associate Director of the Yale Clinic for Attention

More information

The relationship between ADHD and substance use disorder: Evidence based treatment and clinical implications

The relationship between ADHD and substance use disorder: Evidence based treatment and clinical implications Society for the Study of Addiction, York The relationship between ADHD and substance use disorder: Evidence based treatment and clinical implications November 12.th 2010 Soren Dalsgaard, MD, PhD, associate

More information

Attention Deficit Hyperactivity Disorder in Children and Adults

Attention Deficit Hyperactivity Disorder in Children and Adults Attention Deficit Hyperactivity Disorder in Children and Adults Steven R. Pliszka, MD Professor and Chair Department of Psychiatry The University of Texas Health Science Center at San Antonio Speaker Disclosure

More information

Behavioral Health. Behavioral Health. Prescribing Guidelines

Behavioral Health. Behavioral Health. Prescribing Guidelines Behavioral Health Behavioral Health Prescribing Guidelines Attention Deficit/Hyperactivity Disorder (ADHD) Start with a first line medication, either from the methylphenidate or dextroamphetamine-amphetamine

More information

Attention Deficit Hyperactivity Disorder State of the Art. Christopher Okiishi, MD

Attention Deficit Hyperactivity Disorder State of the Art. Christopher Okiishi, MD Attention Deficit Hyperactivity Disorder State of the Art Christopher Okiishi, MD What is ADHD? Three subtypes: Inattentive (under diagnosed, esp. in girls) Hyperactive Impulsive Combined Impairments must

More information

UNIVERSITY OF WISCONSIN LA CROSSE. The ACCESS Center

UNIVERSITY OF WISCONSIN LA CROSSE. The ACCESS Center UNIVERSITY OF WISCONSIN LA CROSSE 165 Murphy Library 1725 State Street La Crosse, WI 54601 Phone: (608) 785-6900 Fax: (608) 785-6910 VERIFICATION OF ATTENTION DEFICIT/HYPERACTIVITY DISORDER (ADHD) provides

More information

Brief Notes on the Mental Health of Children and Adolescents

Brief Notes on the Mental Health of Children and Adolescents Brief Notes on the Mental Health of Children and Adolescents The future of our country depends on the mental health and strength of our young people. However, many children have mental health problems

More information

Students With Attention Deficit Hyperactivity Disorder

Students With Attention Deficit Hyperactivity Disorder On January 29, 2018 the Arizona State Board of Education approved a list of qualified professionals for identification of educational disabilities as developed by the Arizona Department of Education. Categories

More information

ADHD:Updates and Practical Suggestions

ADHD:Updates and Practical Suggestions :Updates and Practical Suggestions Elizabeth Reeve MD HealthPartners Medical Group Disclosure I have no financial disclosures I may be talking about non FDA approved indications for medications Elizabeth.A.Reeve@HealthPartners.com

More information

IRONSHORE TO PRESENT THREE POSTERS AT THE 2019 ANNUAL AMERICAN PROFESSIONAL SOCIETY OF ADHD AND RELATED DISORDERS (APSARD) MEETING

IRONSHORE TO PRESENT THREE POSTERS AT THE 2019 ANNUAL AMERICAN PROFESSIONAL SOCIETY OF ADHD AND RELATED DISORDERS (APSARD) MEETING FOR IMMEDIATE RELEASE IRONSHORE TO PRESENT THREE POSTERS AT THE 2019 ANNUAL AMERICAN PROFESSIONAL SOCIETY OF ADHD AND RELATED DISORDERS (APSARD) MEETING George Town, Cayman Islands January 10, 2019 Ironshore

More information

Pharmacotherapy of Adult ADHD

Pharmacotherapy of Adult ADHD Pharmacotherapy of Adult ADHD Thomas J. Spencer, MD Massachusetts General Hospital Harvard Medical School Disclosures Dr. Spencer receives research support from Royalties and Licensing fees on copyrighted

More information

Case Vignettes ANSWER KEY

Case Vignettes ANSWER KEY Case Vignettes ANSWER KEY CASE 1 Cesar, an 8 year old, 38 kg Hispanic boy, presents to your office, transferring care from another PCP across town. He presents with complaints of significant hyperactivity,

More information

Dose Range. Dose Schedule. Child: 5-60 mg Over 50 kg:5-100 mg Focalin, child: mg Over 50 kg: mg. Focalin: 4-5 hrs.

Dose Range. Dose Schedule. Child: 5-60 mg Over 50 kg:5-100 mg Focalin, child: mg Over 50 kg: mg. Focalin: 4-5 hrs. MEDICATIONS FOR ADHD Group Main Use Medication Brand/ Form Dose Schedule Dose Range Most Common Side Effects for Group Pros for Group Cautions for Group methylphenidate Methylin Focalin (dexmethylphenidate)

More information

Case Study Activity: Management of Attention-Deficit/Hyperactivity Disorder Answers to Interactive Questions and Resources

Case Study Activity: Management of Attention-Deficit/Hyperactivity Disorder Answers to Interactive Questions and Resources Case Study Activity: Management of Attention-Deficit/Hyperactivity Disorder Answers to Interactive Questions and Resources Case 3. Risk of Abuse of ADHD Medications Provider: American Pharmacists Association

More information

ADHD: A Focus On Drug Therapy

ADHD: A Focus On Drug Therapy ADHD: A Focus On Drug Therapy MARY WORTHINGTON, PHARM.D., BCPS MCWHORTER SCHOOL OF PHARMACY BIRMINGHAM, ALABAMA SEPTEMBER 13, 2013 Outpatient Prescription Drug Utilization in US Children, 2002-2010 90

More information

Scottish Medicines Consortium

Scottish Medicines Consortium Scottish Medicines Consortium atomoxetine capsules 10 mg to 60 mg (Strattera ) (153/05) Eli Lilly and Company Ltd No. 4 February 2005 The Scottish Medicines Consortium has completed its assessment of the

More information